The medical community and pharmaceutical industry are increasingly classifying obesity as a chronic disease, a shift that aligns with the rise of new weight-loss medications. This transition in terminology mirrors the historical adoption of disease-based frameworks for mental health conditions, specifically the antidepressant market, and carries significant implications for how healthcare providers treat patients and